6533b7d2fe1ef96bd125e15b

RESEARCH PRODUCT

Malignant lymphoma of the oral cavity and the maxillofacial region: overall survival prognostic factors

Jaime E. Montes-gilJanet Ofelia Guevara-canalesMaria Das Graças Afonso Miranda ChavesSonia Sacsaquispe-contrerasHenrique Duque De Miranda Chaves-nettoCarlos Enrique Cava-vergiúFernando Augusto SoaresRafael Morales-vadilloCarlos Barrionuevo-cornejo

subject

MaleOncologymedicine.medical_specialtyTime FactorsMultivariate analysisLymphomaCross-sectional studyOdontologíasurvivalInternal medicinemedicineHumansStage (cooking)Extranodal InvolvementGeneral DentistrySurvival rateAgedRetrospective StudiesMaxillary NeoplasmsMouth neoplasmOral Medicine and Pathologybusiness.industryRetrospective cohort studyMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Prognosismedicine.disease//purl.org/pe-repo/ocde/ford#3.02.14 [https]Ciencias de la saludSurgeryLymphomaSurvival RateCross-Sectional StudiesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASoral cavityResearch-ArticleFemaleMouth NeoplasmsSurgerybusiness

description

Objective: To identify the overall survival and prognostic factors of malignant lymphoma of the oral cavity and the maxillofacial region. Study Design: Clinical records data were obtained in order to determine overall survival at 2 and 5 years, the individual survival percentage of each possible prognostic factor with the actuarial technique, and the survival regarding the possible prognostic factors with the actuarial technique and the Log-rank and Cox's regression tests. Results: Of 151 subjects, an overall survival was 60% at 2 years, and 45% at 5 years. The multivariate analysis demonstrated statistically significant differences for clinical stage (p=0.002), extranodal involvement (p=0.030), presence of human immunodeficiency virus (p=0.032), and presence of Epstein-Barr virus (p=0.010). Conclusion: The advanced clinical stage and the larger number of involved extranodular sites are related to a lower overall survival, as well as, the presence of previous infections such as the human immunodeficiency and the Epstein-Barr virus.

yearjournalcountryeditionlanguage
2013-05-01
http://hdl.handle.net/10550/35644